AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra. AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback